Aurentz Vincent, Chief Business Officer at EPIRUS Biopharmaceuticals, Inc. (EPRS), bought 2,200 shares at $3.43 ($8K) on 2015-12-17, disclosed to the SEC on 2015-12-21.
Open-market purchase of $8k EPRS by Chief Business Officer. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Nothing distinguishes this filing.